FDMT vs JAZZ · rev $37.0K vs P/E 1988, rev $4.07B
4D Molecular Therapeutics Inc (FDMT) versus Jazz Pharmaceuticals PLC (JAZZ) — a side-by-side from cached financials, not a winner call.
4D Molecular Therapeutics Inc (FDMT) is a biotechnology company listed on US.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Latest reported FDMT revenue for 2024-12-31 was $37.0K. Net income was -$160.9M. Revenue was down 99.8% from 2023-12-31 to 2024-12-31. FDMT currently screens at market cap $518.1M.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
FDMT currently screens at market cap $518.1M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Not investment advice. Open the FDMT and JAZZ stock pages for the full models.
Not investment advice.